Detail
Article
Online article
FT
Medvik - BMC
  • Something wrong with this record ?

Interferon Beta-1a versus Glatiramer Acetate: Changes of Innate Immunity in a Group of Women with Multiple Sclerosis

M. Peterka, M. Valis, O. Soucek, J. Krejsek, L. Sobisek, I. Sejkorova, B. Klimova, P. Stourac, Z. Pavelek, M. Novotny

. 2023 ; 86 (5) : 334-340. [pub] 20230720

Language English Country Switzerland

Document type Journal Article, Research Support, Non-U.S. Gov't

Persistent link   https://www.medvik.cz/link/bmc24001316

INTRODUCTION: Multiple sclerosis (MS) is a chronic inflammatory autoimmune demyelinating disease that secondarily leads to axonal loss and associated brain atrophy. Disease-modifying drugs (DMDs) have previously been studied for their ability to affect specific immunity. This study investigates the effect of interferon beta-1a (INF) and glatiramer acetate (GA) administration on changes in innate immunity cell populations. METHODS: Sixty Caucasian female patients with relapsing-remitting MS undergo blood sample testing for 15 blood parameters at baseline, 1 month, 3 months, and 6 months after treatment by GA or IFN (started as their first-line DMD). RESULTS: A statistically significant difference in the change after 6 months was found in the parameter monocytes (relative count) in the group of patients treated with IFN. The median increase was 27.8%. Changes in many of the other 15 parameters studied were 10-20%. CONCLUSION: Innate immunity has long been neglected in MS immunopathology. The findings suggest that IFN treatment may modulate the immune response in MS by affecting monocyte function and may provide insight into the mechanisms of action of IFN in MS.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc24001316
003      
CZ-PrNML
005      
20240213094538.0
007      
ta
008      
240109s2023 sz f 000 0|eng||
009      
AR
024    7_
$a 10.1159/000532022 $2 doi
035    __
$a (PubMed)37473734
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a sz
100    1_
$a Peterka, Marek $u Department of Neurology, Faculty of Medicine and University Hospital Plzen, Charles University in Prague, Plzen, Czechia
245    10
$a Interferon Beta-1a versus Glatiramer Acetate: Changes of Innate Immunity in a Group of Women with Multiple Sclerosis / $c M. Peterka, M. Valis, O. Soucek, J. Krejsek, L. Sobisek, I. Sejkorova, B. Klimova, P. Stourac, Z. Pavelek, M. Novotny
520    9_
$a INTRODUCTION: Multiple sclerosis (MS) is a chronic inflammatory autoimmune demyelinating disease that secondarily leads to axonal loss and associated brain atrophy. Disease-modifying drugs (DMDs) have previously been studied for their ability to affect specific immunity. This study investigates the effect of interferon beta-1a (INF) and glatiramer acetate (GA) administration on changes in innate immunity cell populations. METHODS: Sixty Caucasian female patients with relapsing-remitting MS undergo blood sample testing for 15 blood parameters at baseline, 1 month, 3 months, and 6 months after treatment by GA or IFN (started as their first-line DMD). RESULTS: A statistically significant difference in the change after 6 months was found in the parameter monocytes (relative count) in the group of patients treated with IFN. The median increase was 27.8%. Changes in many of the other 15 parameters studied were 10-20%. CONCLUSION: Innate immunity has long been neglected in MS immunopathology. The findings suggest that IFN treatment may modulate the immune response in MS by affecting monocyte function and may provide insight into the mechanisms of action of IFN in MS.
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a lidé $7 D006801
650    _2
$a glatiramer acetát $x terapeutické užití $7 D000068717
650    _2
$a interferon beta 1a $x terapeutické užití $7 D000068556
650    12
$a roztroušená skleróza $x farmakoterapie $7 D009103
650    _2
$a interferon beta $x terapeutické užití $7 D016899
650    _2
$a peptidy $x terapeutické užití $7 D010455
650    12
$a relabující-remitující roztroušená skleróza $x farmakoterapie $x patologie $7 D020529
650    _2
$a přirozená imunita $7 D007113
655    _2
$a časopisecké články $7 D016428
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Valis, Martin $u Department of Neurology, Charles University, Faculty of Medicine and University Hospital Hradec Kralove, Hradec Kralove, Czechia
700    1_
$a Soucek, Ondrej $u Department of Clinical Immunology and Allergology, Charles University, Faculty of Medicine and University Hospital Hradec Kralove, Hradec Kralove, Czechia
700    1_
$a Krejsek, Jan $u Department of Clinical Immunology and Allergology, Charles University, Faculty of Medicine and University Hospital Hradec Kralove, Hradec Kralove, Czechia
700    1_
$a Sobisek, Lukáš $u Department of Neurology, Charles University, Faculty of Medicine and University Hospital Hradec Kralove, Hradec Kralove, Czechia
700    1_
$a Sejkorova, Ilona $u Department of Clinical Immunology and Allergology, Charles University, Faculty of Medicine and University Hospital Hradec Kralove, Hradec Kralove, Czechia
700    1_
$a Klimova, Blanka $u Department of Neurology, Charles University, Faculty of Medicine and University Hospital Hradec Kralove, Hradec Kralove, Czechia
700    1_
$a Stourac, Pavel $u Department of Neurology, Masaryk University, Faculty of Medicine and University Brno, Brno, Czechia
700    1_
$a Pavelek, Zbysek $u Department of Neurology, Faculty of Medicine and University Hospital Plzen, Charles University in Prague, Plzen, Czechia
700    1_
$a Novotny, Michal $u Department of Neurology, Charles University, Faculty of Medicine and University Hospital Hradec Kralove, Hradec Kralove, Czechia
773    0_
$w MED00001655 $t European neurology $x 1421-9913 $g Roč. 86, č. 5 (2023), s. 334-340
856    41
$u https://pubmed.ncbi.nlm.nih.gov/37473734 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y - $z 0
990    __
$a 20240109 $b ABA008
991    __
$a 20240213094535 $b ABA008
999    __
$a ok $b bmc $g 2049757 $s 1211010
BAS    __
$a 3
BAS    __
$a PreBMC-MEDLINE
BMC    __
$a 2023 $b 86 $c 5 $d 334-340 $e 20230720 $i 1421-9913 $m European neurology $n Eur Neurol $x MED00001655
LZP    __
$a Pubmed-20240109

Find record

Citation metrics

Archiving options